IGC Pharma/$IGC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About IGC Pharma
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
Ticker
$IGC
Sector
Primary listing
AMEX
Employees
70
Headquarters
Website
IGC Pharma Metrics
BasicAdvanced
$32m
-
-$0.08
0.30
-
Price and volume
Market cap
$32m
Beta
0.3
52-week high
$0.50
52-week low
$0.24
Average daily volume
1.8m
Financial strength
Current ratio
1.324
Quick ratio
0.787
Long term debt to equity
1.693
Total debt to equity
1.804
Profitability
EBITDA (TTM)
-7.524
Gross margin (TTM)
46.20%
Net profit margin (TTM)
-582.82%
Operating margin (TTM)
-731.92%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-50.31%
Return on equity (TTM)
-83.34%
Valuation
Price to revenue (TTM)
23.895
Price to book
3.63
Price to tangible book (TTM)
9.15
Price to free cash flow (TTM)
-4.22
Free cash flow yield (TTM)
-23.69%
Free cash flow per share (TTM)
-0.076
Growth
Revenue change (TTM)
-6.51%
Earnings per share change (TTM)
-57.08%
3-year revenue growth (CAGR)
17.72%
10-year revenue growth (CAGR)
-18.65%
3-year earnings per share growth (CAGR)
-34.20%
10-year earnings per share growth (CAGR)
-9.84%
IGC Pharma News
AllArticlesVideos
IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase
Accesswire·3 days ago
IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia
Accesswire·2 weeks ago
IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout
Accesswire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for IGC Pharma stock?
IGC Pharma (IGC) has a market cap of $32M as of May 01, 2026.
What is the P/E ratio for IGC Pharma stock?
The price to earnings (P/E) ratio for IGC Pharma (IGC) stock is 0 as of May 01, 2026.
Does IGC Pharma stock pay dividends?
No, IGC Pharma (IGC) stock does not pay dividends to its shareholders as of May 01, 2026.
When is the next IGC Pharma dividend payment date?
IGC Pharma (IGC) stock does not pay dividends to its shareholders.
What is the beta indicator for IGC Pharma?
IGC Pharma (IGC) has a beta rating of 0.3. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.